Benjamin K Canales1, Anne L Schafer2, Dolores M Shoback2, Thomas O Carpenter3. 1. Department of Urology, North Florida/South Georgia Veterans Affairs Medical Center and University of Florida, Gainesville, Florida. Electronic address: benjamin.canales@urology.ufl.edu. 2. Endocrine Research Unit, San Francisco Veterans Affairs Medical Center and University of California, San Francisco, California. 3. Department of Pediatrics (Endocrinology), Yale University School of Medicine, New Haven, Connecticut.
Abstract
BACKGROUND: Metabolic bone disease and bariatric surgery have long been interconnected. The objective of this study is to better understand the mechanisms of bone mass loss after Roux-en-Y gastric bypass (RYGB) surgery. We evaluated mineral homeostasis and bone mass in diet-induced obese (DIO) rats after RYGB or sham surgery. METHODS: Twelve DIO male Sprague Dawley rats underwent RYGB (n = 8) or sham (n = 4) surgery at 21 weeks of age. Postoperatively, animals ate an ad libitum 40% fat, normal calcium diet and were euthanized 22 weeks later. Serum and urine chemistries, insulin, leptin, bone turnover markers (BTM), and calciotropic and gut hormones were measured before and 22 weeks after surgery. Femurs were analyzed using microcomputed tomography (µCT). RESULTS: Compared to sham, RYGB animals had lower serum bicarbonate, calcium, 25-hydroxyvitamin D, insulin, and leptin levels with higher serum parathyroid hormone, peptide YY, and urinary calcium at 43 weeks of age. Sham control rats gained weight and had coupled decreases in formation (P1NP and OC) and unchanged resorption (CTX) BTMs. Comparatively, RYGB animals had higher serum CTX and OC but even lower P1NP levels than controls. µCT revealed lower trabecular bone volume, number, and thickness and lower cortical bone volume, thickness, and moment of inertia relative to controls. CONCLUSION: In rats with DIO, long-term RYGB-associated bone resorption appears to be driven in part by vitamin D malabsorption and secondary hyperparathyroidism. Other mechanisms, such as chronic acidosis, changes in fat-secreted hormones, and persistently elevated gut-derived hormone peptide YY, may also contribute to observed bone mass differences. Further investigation of these potential contributors to bone loss may lead to new targets for skeletal maintenance after RYGB.
BACKGROUND:Metabolic bone disease and bariatric surgery have long been interconnected. The objective of this study is to better understand the mechanisms of bone mass loss after Roux-en-Y gastric bypass (RYGB) surgery. We evaluated mineral homeostasis and bone mass in diet-induced obese (DIO) rats after RYGB or sham surgery. METHODS: Twelve DIO male Sprague Dawley rats underwent RYGB (n = 8) or sham (n = 4) surgery at 21 weeks of age. Postoperatively, animals ate an ad libitum 40% fat, normal calcium diet and were euthanized 22 weeks later. Serum and urine chemistries, insulin, leptin, bone turnover markers (BTM), and calciotropic and gut hormones were measured before and 22 weeks after surgery. Femurs were analyzed using microcomputed tomography (µCT). RESULTS: Compared to sham, RYGB animals had lower serum bicarbonate, calcium, 25-hydroxyvitamin D, insulin, and leptin levels with higher serum parathyroid hormone, peptide YY, and urinary calcium at 43 weeks of age. Sham control rats gained weight and had coupled decreases in formation (P1NP and OC) and unchanged resorption (CTX) BTMs. Comparatively, RYGB animals had higher serum CTX and OC but even lower P1NP levels than controls. µCT revealed lower trabecular bone volume, number, and thickness and lower cortical bone volume, thickness, and moment of inertia relative to controls. CONCLUSION: In rats with DIO, long-term RYGB-associated bone resorption appears to be driven in part by vitamin Dmalabsorption and secondary hyperparathyroidism. Other mechanisms, such as chronic acidosis, changes in fat-secreted hormones, and persistently elevated gut-derived hormone peptide YY, may also contribute to observed bone mass differences. Further investigation of these potential contributors to bone loss may lead to new targets for skeletal maintenance after RYGB.
Authors: Kerstin Stemmer; Maximilian Bielohuby; Bernadette E Grayson; Denovan P Begg; Adam P Chambers; Christina Neff; Stephen C Woods; Reinhold G Erben; Matthias H Tschöp; Martin Bidlingmaier; Thomas L Clemens; Randy J Seeley Journal: Endocrinology Date: 2013-04-03 Impact factor: 4.736
Authors: Jason M Johnson; James W Maher; Isaac Samuel; Deborah Heitshusen; Cornelius Doherty; Robert W Downs Journal: J Gastrointest Surg Date: 2005-11 Impact factor: 3.452
Authors: Penelope S Coates; John D Fernstrom; Madelyn H Fernstrom; Philip R Schauer; Susan L Greenspan Journal: J Clin Endocrinol Metab Date: 2004-03 Impact factor: 5.958
Authors: Juan P Valderas; Verónica Irribarra; Camilo Boza; Rolando de la Cruz; Yessica Liberona; Ana Maria Acosta; Macarena Yolito; Alberto Maiz Journal: J Clin Endocrinol Metab Date: 2010-01-22 Impact factor: 5.958
Authors: Melissa Russell; Jenna Stark; Shriddha Nayak; Karen K Miller; David B Herzog; Anne Klibanski; Madhusmita Misra Journal: Bone Date: 2009-04-01 Impact factor: 4.398
Authors: Aidi Niu; Thomas O Carpenter; Jayleen M Grams; Shahab Bozorgmehri; Steven M Tommasini; Anne L Schafer; Benjamin K Canales Journal: Bone Date: 2019-06-19 Impact factor: 4.398
Authors: Madhusmita Misra; Vibha Singhal; Brian Carmine; Amita Bose; Megan M Kelsey; Fatima Cody Stanford; Jennifer Bram; Jeremy Aidlen; Thomas Inge; Mary L Bouxsein; Miriam A Bredella Journal: Bone Date: 2020-02-19 Impact factor: 4.398